• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Epidemiol Infect . Development of a nomogram for high antibody titre of COVID-19 convalescent plasma

tetano

Editor, Senior Moderator
Epidemiol Infect


. 2024 Dec 11:152:e167.
doi: 10.1017/S0950268824001638. Development of a nomogram for high antibody titre of COVID-19 convalescent plasma

Shichun Wang[SUP] 1 [/SUP], Jie Yan[SUP] 1 [/SUP], Min Song[SUP] 1 [/SUP], Zhenrui Xue[SUP] 1 [/SUP], Zerong Wang[SUP] 1 [/SUP], Ronghua Diao[SUP] 1 [/SUP], Qi Liu[SUP] 1 [/SUP], Qianying Ruan[SUP] 1 [/SUP], Chunyan Yao[SUP] 1 2 [/SUP]



Affiliations
Abstract

This study aimed to develop a predictive tool for identifying individuals with high antibody titers crucial for recruiting COVID-19 convalescent plasma (CCP) donors and to assess the quality and storage changes of CCP. A convenience sample of 110 plasma donors was recruited, of which 75 met the study criteria. Using univariate logistic regression and random forest, 6 significant factors were identified, leading to the development of a nomogram. Receiver operating characteristic curves, calibration plots, and decision curve analysis (DCA) evaluated the nomogram's discrimination, calibration, and clinical utility. The nomogram indicated that females aged 18 to 26, blood type O, receiving 1 to 2 COVID-19 vaccine doses, experiencing 2 symptoms during infection, and donating plasma 41 to 150 days after symptom onset had higher likelihoods of high antibody titres. Nomogram's AUC was 0.853 with good calibration. DCA showed clinical benefit within 9% ~ 90% thresholds. CCP quality was qualified, with stable antibody titres over 6 months (P > 0.05). These findings highlight developing predictive tools to identify suitable CCP donors and emphasize the stability of CCP quality over time, suggesting its potential for long-term storage.

Keywords: COVID-19 convalescent plasma; SARS-CoV-2 IgG; nomogram plasma donation; predictive factors.

 
Back
Top Bottom